LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,149
تعداد مقالات10,519
تعداد مشاهده مقاله45,426,919
تعداد دریافت فایل اصل مقاله11,296,878
Owji, Seyed Mohammad, Raeisi Shahraki, Hadi, Owji, Seyed Hossein. (1399). A 16-year Survey of Clinicopathological Findings, Electron Microscopy, and Classification of Renal Amyloidosis. سامانه مدیریت نشریات علمی, 46(1), 32-42. doi: 10.30476/ijms.2019.82110.
Seyed Mohammad Owji; Hadi Raeisi Shahraki; Seyed Hossein Owji. "A 16-year Survey of Clinicopathological Findings, Electron Microscopy, and Classification of Renal Amyloidosis". سامانه مدیریت نشریات علمی, 46, 1, 1399, 32-42. doi: 10.30476/ijms.2019.82110.
Owji, Seyed Mohammad, Raeisi Shahraki, Hadi, Owji, Seyed Hossein. (1399). 'A 16-year Survey of Clinicopathological Findings, Electron Microscopy, and Classification of Renal Amyloidosis', سامانه مدیریت نشریات علمی, 46(1), pp. 32-42. doi: 10.30476/ijms.2019.82110.
Owji, Seyed Mohammad, Raeisi Shahraki, Hadi, Owji, Seyed Hossein. A 16-year Survey of Clinicopathological Findings, Electron Microscopy, and Classification of Renal Amyloidosis. سامانه مدیریت نشریات علمی, 1399; 46(1): 32-42. doi: 10.30476/ijms.2019.82110.

A 16-year Survey of Clinicopathological Findings, Electron Microscopy, and Classification of Renal Amyloidosis

Iranian Journal of Medical Sciences
مقاله 4، دوره 46، شماره 1، فروردین 2021، صفحه 32-42    اصل مقاله (2.75 M)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/ijms.2019.82110.
نویسندگان
Seyed Mohammad Owji1؛ Hadi Raeisi Shahraki2؛ Seyed Hossein Owji* 3
1Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
2Department of Epidemiology and Biostatistics, School of Health, Shahrekord University of Medical Sciences, Shahrekord, Iran
3Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
چکیده
Background: Electron microscopy (EM) is a valuable tool in the diagnosis of renal amyloidosis, particularly in the early stages of the disease. In Iran, studies on EM and the clinical features of renal amyloidosis are scarce. The objective of the present study was to survey EM investigations, pathological classifications, and clinical features of renal amyloidosis.
Methods: This cross-sectional study was performed in Shiraz, Iran, during 2001-2016. Out of 2,770 kidney biopsies, 27 cases with a diagnosis of renal amyloidosis were investigated. EM investigation and six staining procedures for light microscopy (LM) were performed. Two pathological classifications based on glomerular, peritubular, perivascular, and interstitial involvement were made. Finally, the association between these classifications and the clinical features was assessed. Chi-square, Fisher’s exact, Independent t test, and Multiple logistic regression analysis were used. P valuesResults: In 51.9% of the cases, the clinical diagnosis was nephrotic syndrome. Proteinuria and edema were the most prevalent clinical manifestations. The role of EM investigation for diagnosis was graded “necessary” or “supportive” in 48.2% of the patients. In the classification based on glomerular classes, variables such as the mean blood pressure (P=0.003), history of hypertension (P=0.02), creatinine >1.5 (P=0.03), and severe tubular atrophy (P=0.03) were significantly higher in class B (advanced amyloid depositions).
Conclusion: EM plays an important role in the diagnosis of renal amyloidosis. EM in conjunction with LM investigation with Congo red staining is recommended, to prevent misdiagnosis of patients with a clinical suspicion of renal amyloidosis. Among different pathological features of renal amyloidosis, the severity of glomerular amyloid depositions had a clear relationship with clinical presentations.
کلیدواژه‌ها
Amyloidosis؛ Microscopy؛ Electrons؛ Proteinuria؛ Nephrotic syndrome؛ Kidney
سایر فایل های مرتبط با مقاله
مراجع
  1. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, et al. Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid. 2014;21:221-4. doi: 10.3109/13506129.2014.964858. PubMed PMID: 25263598.
  2. Bustamante JG, Gossman WG. Amyloidosis. StatPearls: StatPearls Publishing; 2019.
  3. Said SM, Sethi S, Valeri AM, Leung N, Cornell LD, Fidler ME, et al. Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol. 2013;8:1515-23. doi: 10.2215/CJN.10491012. PubMed PMID: 23704299; PubMed Central PMCID: PMCPMC3805078.
  4. Gertz MA. Amyloidosis: diagnosis and prognosis. International Journal of Clinical Rheumatology. 2008;3:369. doi: 10.2217/17460816.3.4.369.
  5. Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho AD, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124:2325-32. doi: 10.1182/blood-2014-04-570010. PubMed PMID: 25115890.
  6. Rysava R. AL amyloidosis with renal involvement. Kidney Blood Press Res. 2007;30:359-64. doi: 10.1159/000107980. PubMed PMID: 17851224.
  7. Keeling J, Teng J, Herrera GA. AL-amyloidosis and light-chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells. Lab Invest. 2004;84:1322-38. doi: 10.1038/labinvest.3700161. PubMed PMID: 15286662.
  8. Sasatomi Y, Kiyoshi Y, Uesugi N, Hisano S, Takebayashi S. Prognosis of renal amyloidosis: a clinicopathological study using cluster analysis. Nephron. 2001;87:42-9. doi: 10.1159/000045883. PubMed PMID: 11174025.
  9. Sen S, Sarsik B. A proposed histopathologic classification, scoring, and grading system for renal amyloidosis: standardization of renal amyloid biopsy report. Arch Pathol Lab Med. 2010;134:532-44. doi: 10.1043/1543-2165-134.4.532. PubMed PMID: 20367305.
  10. Picken MM. Amyloidosis-where are we now and where are we heading? Arch Pathol Lab Med. 2010;134:545-51. doi: 10.1043/1543-2165-134.4.545. PubMed PMID: 20367306.
  11. Owji M, Modarressi F, Geramizadeh B, Haghighi AB, Alizadeh A, Heidari T. Diagnosis of Myopathies Using Histology, Histochemistry, Immunohistochemistry and Electron Microscopy: A Single Center Experience. Iran Red Crescent Med J. 2010;12:434-40.
  12. Watanabe T, Saniter T. Morphological and clinical features of renal amyloidosis. Virchows Arch A Pathol Anat Histol. 1975;366:125-35. doi: 10.1007/BF00433586. PubMed PMID: 805487.
  13. Kalle A, Gudipati A, Raju SB, Kalidindi K, Guditi S, Taduri G, et al. Revisiting renal amyloidosis with clinicopathological characteristics, grading, and scoring: A single-institutional experience. J Lab Physicians. 2018;10:226-31. doi: 10.4103/JLP.JLP_148_17. PubMed PMID: 29692592; PubMed Central PMCID: PMCPMC5896193.
  14. Ozawa M, Komatsuda A, Ohtani H, Nara M, Sato R, Togashi M, et al. Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience. Clin Exp Nephrol. 2017;21:212-27. doi: 10.1007/s10157-016-1271-y. PubMed PMID: 27116248.
  15. Castano E, Palmer MB, Vigneault C, Luciano R, Wong S, Moeckel G. Comparison of amyloid deposition in human kidney biopsies as predictor of poor patient outcome. BMC Nephrol. 2015;16:64. doi: 10.1186/s12882-015-0046-0. PubMed PMID: 25924613; PubMed Central PMCID: PMCPMC4424547.
  16. Alexander MP, Dasari S, Vrana JA, Riopel J, Valeri AM, Markowitz GS, et al. Congophilic Fibrillary Glomerulonephritis: A Case Series. Am J Kidney Dis. 2018;72:325-36. doi: 10.1053/j.ajkd.2018.03.017. PubMed PMID: 29866458.
  17. Luo CQ, Zhang YA, Li ZQ, Wang YM. Clinicopathological features of renal amyloidosis: a single-center study on 47 cases. J Huazhong Univ Sci Technolog Med Sci. 2015;35:48-53. doi: 10.1007/s11596-015-1387-4. PubMed PMID: 25673192.
  18. Engineer DP, Kute VB, Patel HV, Shah PR. Clinical and laboratory profile of renal amyloidosis: A single-center experience. Saudi J Kidney Dis Transpl. 2018;29:1065-72. doi: 10.4103/1319-2442.243966. PubMed PMID: 30381502.
  19. Matsuda M, Katoh N, Ikeda S. Clinical manifestations at diagnosis in Japanese patients with systemic AL amyloidosis: a retrospective study of 202 cases with a special attention to uncommon symptoms. Intern Med. 2014;53:403-12. doi: 10.2169/internalmedicine.53.0898. PubMed PMID: 24583427.
  20. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003;361:117-24. doi: 10.1016/S0140-6736(03)12229-5. PubMed PMID: 12531578.
  21. Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res. 2014;37:253-390. doi: 10.1038/hr.2014.20. PubMed PMID: 24705419.
  22. Sasatomi Y, Sato H, Chiba Y, Abe Y, Takeda S, Ogahara S, et al. Prognostic factors for renal amyloidosis: a clinicopathological study using cluster analysis. Intern Med. 2007;46:213-9. doi: 10.2169/internalmedicine.46.1690. PubMed PMID: 17329915.
  23. Uluhan A, Paydas S, Sagliker Y, Demirtas M, Bozdemir H, Sarica Y. Low blood pressure and amyloidosis. Nephron. 1995;69:118-9. doi: 10.1159/000188385. PubMed PMID: 7891788.
  24. Labib A, Shakweer MM, Salman MI, Seif EI. Is renal amyloidosis uncommon in Egypt? A-25-year study. Journal of Nephropathology. 2019;8:1-8. doi: 10.15171/jnp.2019.05.
  25. Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356:2361-71. doi: 10.1056/NEJMoa070265. PubMed PMID: 17554117.
  26. Bergesio F, Ciciani AM, Santostefano M, Brugnano R, Manganaro M, Palladini G, et al. Renal involvement in systemic amyloidosis--an Italian retrospective study on epidemiological and clinical data at diagnosis. Nephrol Dial Transplant. 2007;22:1608-18. doi: 10.1093/ndt/gfm041. PubMed PMID: 17395661.
  27. Nakamura T. Clinical strategies for amyloid A amyloidosis secondary to rheumatoid arthritis. Mod Rheumatol. 2008;18:109-18. doi: 10.1007/s10165-008-0035-2. PubMed PMID: 18369528.
  28. Pamuk ON, Donmez S, Pamuk GE, Puyan FO, Keystone EC. Turkish experience in rheumatoid arthritis patients with clinical apparent amyloid deposition. Amyloid. 2013;20:245-50. doi: 10.3109/13506129.2013.840576. PubMed PMID: 24106838.
  29. Younes M, Korbaa W, Moussa A, Zrour S, Bejia I, Touzi M, et al. Prevalence of subclinical amyloidosis in Tunisian patients with rheumatoid arthritis. Joint Bone Spine. 2009;76:254-9. doi: 10.1016/j.jbspin.2008.08.009. PubMed PMID: 19303802.
  30. Mwamunyi MJ, Xiang H, Yao L-j. Prognostic factors of poor renal outcomes in renal amyloidosis patients: Systematic review and meta-analysis. International Journal of Scientific Research and Management. 2019;7. doi: 10.18535/ijsrm/v7i1.mp01.
آمار
تعداد مشاهده مقاله: 3,784
تعداد دریافت فایل اصل مقاله: 2,667


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب